DE69131021T2 - Angiotensin-ii-rezeptor blockierende zusammensetzungen - Google Patents

Angiotensin-ii-rezeptor blockierende zusammensetzungen

Info

Publication number
DE69131021T2
DE69131021T2 DE69131021T DE69131021T DE69131021T2 DE 69131021 T2 DE69131021 T2 DE 69131021T2 DE 69131021 T DE69131021 T DE 69131021T DE 69131021 T DE69131021 T DE 69131021T DE 69131021 T2 DE69131021 T2 DE 69131021T2
Authority
DE
Germany
Prior art keywords
angiotensin
receptor blocking
blocking compositions
blocker
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131021T
Other languages
English (en)
Other versions
DE10399008I1 (de
DE69131021D1 (de
Inventor
Joseph Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69131021D1 publication Critical patent/DE69131021D1/de
Publication of DE69131021T2 publication Critical patent/DE69131021T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69131021T 1990-12-14 1991-12-13 Angiotensin-ii-rezeptor blockierende zusammensetzungen Expired - Lifetime DE69131021T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62880790A 1990-12-14 1990-12-14
PCT/US1991/009362 WO1992010097A1 (en) 1990-12-14 1991-12-13 Angiotensin ii receptor blocking compositions

Publications (2)

Publication Number Publication Date
DE69131021D1 DE69131021D1 (de) 1999-04-22
DE69131021T2 true DE69131021T2 (de) 1999-08-12

Family

ID=24520386

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69131021T Expired - Lifetime DE69131021T2 (de) 1990-12-14 1991-12-13 Angiotensin-ii-rezeptor blockierende zusammensetzungen
DE1991631021 Pending DE10399008I1 (de) 1990-12-14 1991-12-13 Angiotensin-II-Rezeptor blockierende Zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1991631021 Pending DE10399008I1 (de) 1990-12-14 1991-12-13 Angiotensin-II-Rezeptor blockierende Zusammensetzungen

Country Status (14)

Country Link
EP (1) EP0565634B1 (de)
JP (1) JP3398379B2 (de)
KR (1) KR100222252B1 (de)
AT (1) ATE177634T1 (de)
AU (1) AU656551B2 (de)
CA (1) CA2098176C (de)
DE (2) DE69131021T2 (de)
DK (1) DK0565634T3 (de)
ES (1) ES2130170T3 (de)
GR (1) GR3030293T3 (de)
HK (1) HK1012209A1 (de)
LU (1) LU91234I2 (de)
NL (1) NL300115I2 (de)
WO (1) WO1992010097A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
KR19990087076A (ko) * 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
WO1997049392A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
ES2273433T3 (es) * 1997-08-06 2007-05-01 Smithkline Beecham Corporation Complejo por neutralizacion de cargas con arginilo de eprosartan y procedimiento para su produccion y formulacion.
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
JP4575594B2 (ja) * 1998-07-20 2010-11-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 経口用固体剤形のエプロサルタン配合の生体内強化性処方
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
TW200306799A (en) * 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
NZ536555A (en) 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
KR101194453B1 (ko) 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
EP2626354A1 (de) 2004-02-20 2013-08-14 Boehringer Ingelheim International GmbH Viren-Polymerasehemmer
CA2557665A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20080161321A1 (en) * 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
CN101534798B (zh) * 2006-10-30 2012-02-15 韩诺生物制约株式会社 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
EP2170930B3 (de) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110111022A1 (en) 2008-04-10 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical formulation
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20150007297A (ko) 2012-05-07 2015-01-20 바이엘 파마 악티엔게젤샤프트 니페디핀 및 칸데사르탄 실렉세틸을 포함하는 제약 투여 형태의 제조 방법
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (de) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0955294B1 (de) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazoalkensäure
TW201738B (de) * 1990-03-20 1993-03-11 Sanofi Co
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
DE10399008I1 (de) 2006-06-08
DK0565634T3 (da) 1999-09-27
DE69131021D1 (de) 1999-04-22
NL300115I1 (nl) 2003-05-01
KR100222252B1 (ko) 1999-10-01
EP0565634B1 (de) 1999-03-17
EP0565634A4 (en) 1996-04-17
NL300115I2 (nl) 2003-09-01
KR930702895A (ko) 1993-11-29
ATE177634T1 (de) 1999-04-15
CA2098176A1 (en) 1992-06-14
JPH06503834A (ja) 1994-04-28
AU9178291A (en) 1992-07-08
EP0565634A1 (de) 1993-10-20
JP3398379B2 (ja) 2003-04-21
AU656551B2 (en) 1995-02-09
GR3030293T3 (en) 1999-09-30
WO1992010097A1 (en) 1992-06-25
HK1012209A1 (en) 1999-07-30
LU91234I2 (fr) 2006-06-12
CA2098176C (en) 2006-12-12
ES2130170T3 (es) 1999-07-01

Similar Documents

Publication Publication Date Title
DE10399008I1 (de) Angiotensin-II-Rezeptor blockierende Zusammensetzungen
RU2012110522A (ru) Гипотензивная комбинация валсартана и блокатора кальциевых каналов
NO996352D0 (no) <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
GR3034485T3 (en) Tricyclic substituted hexahydrobenz e]isoindole alpha-1 adrenergic antagonists
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
EA200200503A1 (ru) Способ лечения ревматоидного артрита
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
IL122242A0 (en) Combination of angiotensin II receptor and epoxy-steroidal aldosterone receptor antagonist
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
IL70882A0 (en) Certain benzazocinone and benzazoninone derivatives
MX9202243A (es) Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.
EP0726072A3 (de) Zusammenstellung zur Behandlung von Hypertonie und congestiven Herzensagens, die ein Angiotensin-II-Antagonist und ein Endopeptidase Inhibitor enthält
AU3498795A (en) Method of blocking the sec receptor
ES2175437T3 (es) Composicion de enalapril y losartan.
ATA156496A (de) Pharmazeutische zusammensetzung
NO992661L (no) Benzopyranopyrrol og benzopyranopyridin <alfa>-1 adrenerge forbindelser
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
EA199800889A1 (ru) Способ предупреждения и/или лечения сердечной недостаточности и дисфункции желудочков антагонистами эндотелина, фармацевтическая композиция
AR011730A1 (es) UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA
GR3030353T3 (en) Composite cement
EA199800533A1 (ru) Композиция для лечения боли
IL130642A0 (en) N-(pyridinylamino)isoindolines and related compounds
WO2000076457A3 (en) Il-8 receptor antagonists
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: EPROSARTANMESILAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: 50260.00.00, 20021002

Spc suppl protection certif: 103 99 008

Filing date: 20030312

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: EPROSARTANMESILAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: 50260.00.00, 20021002

Spc suppl protection certif: 103 99 008

Filing date: 20030312

V457 Spc granted

Free format text: PRODUCT NAME: EPROSARTANMESILAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: 50260.00.00, 20021002

Spc suppl protection certif: 103 99 008

Filing date: 20030312